Pfizer Inc (PFE) - Stock Report

First-quarter 2026 gave Pfizer real but not decisive cash-conversion proof: revenue rose 5% to $14.45 bn, or 2% operationally, and grew 7% operationally excluding Comirnaty and Paxlovid. Launched and acquired products grew 22% operationally, with Padcev, Nurtec/Vydura and Lorbrena showing the replacement assets can move the revenue bridge. The quarter should not be annualized mechanically because some gains benefited one-time net-price, supply-recovery or returns-comparison effects, and COVID-product declines still distort the mix. Reported diluted EPS was $0.47, adjusted diluted EPS was $0.75, operating cash flow was $2.62 bn, and a post-capex proxy of about $2.18 bn sat roughly $0.27 bn below the $2.45 bn cash dividend outlay, with no 2026 buybacks assumed in guidance.

The key macro issue is not rates or patent cliffs in isolation, but whether mature-product net-price and exclusivity pressure can be replaced by launches that convert into reported post-capex cash: if oncology, specialty-care and acquired assets scale while debt falls, Pfizer can defend the dividend and valuation; if replacement growth arrives at lower margins or with heavier spending, the same revenue base leaves shareholders with tighter coverage and a capped multiple.

Pfizer is a global biopharma company whose economics come from discovering, buying, developing, manufacturing and commercializing patent-protected medicines and vaccines. The portfolio is mixed: branded therapies led by biologics and antibody-drug conjugates, plus small molecules, vaccines, sterile injectables, biosimilars and alliance products. That distinction matters because biologics face biosimilars, small molecules face generics, and each erosion path has different timing and pricing pressure.

The operating model is now almost entirely Biopharma, with Pfizer CentreOne adding a small contract-manufacturing role. Inside Biopharma, the economic work is split across established cash products such as Eliquis, Vyndaqel/Vyndamax and Prevnar-family vaccines; oncology replacement assets such as Padcev, Lorbrena, Braftovi and Seagen-derived antibody-drug conjugates; migraine and specialty launches such as Nurtec/Vydura; hospital and biosimilar products; and COVID products that remain seasonal and declining.

Management is running a cash-preservation transition. The 2026 plan keeps revenue guidance at $59.5 bn to $62.5 bn and adjusted diluted EPS at $2.80 to $3.00 while absorbing an expected roughly $1.5 bn revenue hit from generic and biosimilar competition. The priority is converting Seagen, Metsera and internal oncology/obesity programs into replacement revenue while using cost realignment and manufacturing optimization to protect the dividend and reduce leverage.